GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Price-to-Free-Cash-Flow

Chiome Bioscience (TSE:4583) Price-to-Free-Cash-Flow : N/A (As of Sep. 22, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Price-to-Free-Cash-Flow?

As of today (2024-09-22), Chiome Bioscience's share price is 円111.00. Chiome Bioscience's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was 円0.00. Hence, Chiome Bioscience's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Chiome Bioscience's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Chiome Bioscience's highest Price-to-Free-Cash-Flow Ratio was 68.57. The lowest was 0.00. And the median was 68.20.

TSE:4583's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.86
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Chiome Bioscience's Free Cash Flow per Share for the three months ended in Jun. 2024 was 円0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was 円0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 17.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 19.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 3.90% per year.

During the past 13 years, Chiome Bioscience's highest 3-Year average Free Cash Flow per Share Growth Rate was 23.60% per year. The lowest was -168.20% per year. And the median was -1.75% per year.


Chiome Bioscience Price-to-Free-Cash-Flow Historical Data

The historical data trend for Chiome Bioscience's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Price-to-Free-Cash-Flow Chart

Chiome Bioscience Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Chiome Bioscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chiome Bioscience's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Chiome Bioscience's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Price-to-Free-Cash-Flow falls into.



Chiome Bioscience Price-to-Free-Cash-Flow Calculation

Chiome Bioscience's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=111.00/0
=N/A

Chiome Bioscience's Share Price of today is 円111.00.
Chiome Bioscience's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Chiome Bioscience  (TSE:4583) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Chiome Bioscience Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiome Bioscience Business Description

Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience Headlines

No Headlines